Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & Lopez-Soto, A. The hallmarks of profitable anticancer immunotherapy. Sci. Transl. Med. 10, eaat7807 (2018).
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A information to most cancers immunotherapy: from T cell primary science to medical follow. Nat. Rev. Immunol. 20, 651–668 (2020).
Carlino, M. S., Larkin, J. & Lengthy, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002–1014 (2021).
Carlisle, J. W., Steuer, C. E., Owonikoko, T. Ok. & Saba, N. F. An replace on the immune panorama in lung and head and neck cancers. CA Most cancers J. Clin. 70, 505–517 (2020).
Atkins, M. B., Clark, J. I. & Quinn, D. I. Immune checkpoint inhibitors in superior renal cell carcinoma: expertise to this point and future instructions. Ann. Oncol. 28, 1484–1494 (2017).
Ribas, A. & Wolchok, J. D. Most cancers immunotherapy utilizing checkpoint blockade. Science 359, 1350–1355 (2018).
Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).
O’Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Most cancers immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019).
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for most cancers remedy: mechanisms, response biomarkers, and mixtures. Sci. Transl. Med. 8, 328rv324 (2016).
Hirsch, L., Zitvogel, L., Eggermont, A. & Marabelle, A. PD-Loma: a most cancers entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br. J. Most cancers 120, 3–5 (2019).
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy within the period of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725–741 (2020).
Voorwerk, L. et al. Immune induction methods in metastatic triple-negative breast most cancers to boost the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920–928 (2019).
Pujade-Lauraine, E. et al. Avelumab alone or together with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian most cancers (JAVELIN Ovarian 200): an open-label, three-arm, randomised, section 3 examine. Lancet Oncol. 22, 1034–1046 (2021).
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and dying. Nat. Immunol. 23, 487–500 (2022).
Fucikova, J. et al. Detection of immunogenic cell dying and its relevance for most cancers remedy. Cell Demise Dis. 11, 1013 (2020).
Krysko, D. V. et al. Immunogenic cell dying and DAMPs in most cancers remedy. Nat. Rev. Most cancers 12, 860–875 (2012).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to most cancers therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in most cancers development and response to immunotherapy. Nat. Med. 27, 212–224 (2021).
Marusyk, A., Janiszewska, M. & Polyak, Ok. Intratumor heterogeneity: the Rosetta stone of remedy resistance. Most cancers Cell 37, 471–484 (2020).
Loh, J. J. & Ma, S. Hallmarks of most cancers stemness. Cell Stem Cell 31, 617–639 (2024).
Bayik, D. & Lathia, J. D. Most cancers stem cell–immune cell crosstalk in tumour development. Nat. Rev. Most cancers 21, 526–536 (2021).
Lytle, N. Ok., Barber, A. G. & Reya, T. Stem cell destiny in most cancers development, development and remedy resistance. Nat. Rev. Most cancers 18, 669–680 (2018).
Schatton, T. et al. Modulation of T-cell activation by malignant melanoma initiating cells. Most cancers Res. 70, 697–708 (2010).
Castagnoli, L. et al. WNT signaling modulates PD-L1 expression within the stem cell compartment of triple-negative breast most cancers. Oncogene 38, 4047–4060 (2019).
Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on most cancers stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).
Miao, Y. et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell 177, 1172–1186.e14 (2019).
Taniguchi, S. et al. Tumor-initiating cells set up an IL-33-TGF-β area of interest signaling loop to advertise most cancers development. Science 369, eaay1813 (2020).
Derynck, R., Turley, S. J. & Akhurst, R. J. TGFβ biology in most cancers development and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9–34 (2021).
Zhang, Q. et al. CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast most cancers. Most cancers Res. 75, 4312–4321 (2015).
Liu, C. et al. ALDH1A1 exercise in tumor-initiating cells remodels myeloid-derived suppressor cells to advertise breast most cancers development. Most cancers Res. 81, 5919–5934 (2021).
Yin, J. et al. ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nat. Commun. 11, 2978 (2020).
Shidal, C., Singh, N. P., Nagarkatti, P. & Nagarkatti, M. MicroRNA-92 expression in CD133+ melanoma stem cells regulates immunosuppression within the tumor microenvironment through integrin-dependent activation of TGFβ. Most cancers Res. 79, 3622–3635 (2019).
Chen, P., Hsu, W. H., Han, J., Xia, Y. & DePinho, R. A. Most cancers stemness meets immunity: from mechanism to remedy. Cell Rep. 34, 108597 (2021).
Galluzzi, L. & Kroemer, G. Immuno-epigenetic escape of most cancers stem cells. Nat. Immunol. 23, 1300–1302 (2022).
Blanco-Fernandez, G., Blanco-Fernandez, B., Fernández-Ferreiro, A. & Otero-Espinar, F. Bringing lipidic lyotropic liquid crystal expertise into biomedicine. Developments Pharmacol. Sci. 44, 7–10 (2022).
Rajabalaya, R., Musa, M. N., Kifli, N. & David, S. R. Oral and transdermal drug supply programs: position of lipid-based lyotropic liquid crystals. Drug Des. Devel. Ther. 11, 393–406 (2017).
Wang, Z. Y. & Chen, Z. Acute promyelocytic leukemia: from extremely deadly to extremely curable. Blood 111, 2505–2515 (2008).
Nguyen, P. H. et al. All-trans retinoic acid targets gastric most cancers stem cells and inhibits patient-derived gastric carcinoma tumor development. Oncogene 35, 5619–5628 (2016).
Yao, W. et al. All-trans retinoic acid reduces most cancers stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. BMC Most cancers 20, 315 (2020).
Li, R. J. et al. All-trans retinoic acid stealth liposomes forestall the relapse of breast most cancers arising from the most cancers stem cells. J. Management. Launch 149, 281–291 (2011).
Solar, R. et al. Co-delivery of all-trans-retinoic acid and doxorubicin for most cancers remedy with synergistic inhibition of most cancers stem cells. Biomaterials 37, 405–414 (2015).
Shen, S. et al. A nanotherapeutic technique to beat chemotherapeutic resistance of most cancers stem-like cells. Nat. Nanotechnol. 16, 104–113 (2021).
Luo, Y. et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30, 2100–2113 (2012).
Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008).
Obeid, M. et al. Calreticulin publicity dictates the immunogenicity of most cancers cell dying. Nat. Med. 13, 54–61 (2007).
Mu, L. M. et al. Growth of useful dendrisomes based mostly on a single molecule of polyesterbenzylether dendrimer and their software in most cancers stem cell remedy. NPG Asia Mater. 11, 34 (2019).
Chen, X. Y. et al. Differentiation-inducing and anti-proliferative actions of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: mechanisms profiling by RNA-seq. Gene 592, 86–98 (2016).
Silvestrini, A. V. P., Caron, A. L., Viegas, J., Praça, F. G. & Bentley, M. Advances in lyotropic liquid crystal programs for pores and skin drug supply. Skilled Opin. Drug Deliv. 17, 1781–1805 (2020).
Wang, B. et al. Self-assembling in situ gel based mostly on lyotropic liquid crystals containing VEGF for tissue regeneration. Acta Biomater. 99, 84–99 (2019).
Chen, Q. et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical most cancers therapy. Nat. Nanotechnol. 14, 89–97 (2019).
Wang, C. et al. In situ fashioned reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for mixture remedy. Sci. Transl. Med. 10, eaan3682 (2018).
Jiang, G. et al. Single-cell transcriptomics reveal the heterogeneity and dynamic of most cancers stem-like cells throughout breast tumor development. Cell Demise Dis. 12, 979 (2021).
Attalla, S., Taifour, T., Bui, T. & Muller, W. Insights from transgenic mouse fashions of PyMT-induced breast most cancers: recapitulating human breast most cancers development in vivo. Oncogene 40, 475–491 (2021).
Chao, Y. et al. Localized cocktail chemoimmunotherapy after in situ gelation to set off strong systemic antitumor immune responses. Sci. Adv. 6, eaaz4204 (2020).
Lofwall, M. R. et al. Weekly and month-to-month subcutaneous buprenorphine depot formulations vs each day sublingual buprenorphine with naloxone for therapy of opioid use dysfunction: a randomized medical trial. JAMA Intern. Med. 178, 764–773 (2018).
Wei, J. et al. A bioadhesive barrier-forming oral liquid gel improved oral mucositis and dietary standing in sufferers with head and neck cancers present process radiotherapy: a retrospective single middle examine. Entrance. Oncol. 11, 617392 (2021).
Barauskas, J. et al. Bioadhesive lipid compositions: self-assembly constructions, performance, and medical functions. Mol. Pharm. 11, 895–903 (2014).